Clinical Trials Logo

Right Ventricular Dilatation clinical trials

View clinical trials related to Right Ventricular Dilatation.

Filter by:
  • None
  • Page 1

NCT ID: NCT04345796 Recruiting - Clinical trials for Tricuspid Regurgitation

Pharmacological Reduction of Right Ventricular Enlargement

PROVE
Start date: February 15, 2021
Phase: Phase 3
Study type: Interventional

Functional tricuspid regurgitation (TR) has been regarded as a secondary phenomenon of heart failure (HF), mitral valve (MV) disease or atrial fibrillation. Regardless of left ventricular (LV) function or pulmonary artery pressure, presence of moderate or greater functional TR is associated with poor prognosis. When a patient develops functional TR, it causes RV dilation and tricuspid annular enlargement, which also lead to deterioration of TR. A vicious cycle of significant TR, RV volume overload, tricuspid annular dilation and consequent aggravation of TR is accepted as a main determinant of the poor clinical outcome of patients with TR. Therefore, therapies that induce reverse remodeling of the RV and consequently reduce TR, may improve clinical outcomes. However, there have been no proven medical therapies for TR. The investigators hypothesize that carvedilol or empagliflozin is effective on improving RV remodeling in patients with functional severe TR and try to examine this hypothesis in a multicenter, 2x2 factorial, and randomized comparison study using cardiac MRI.